EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – FDA Type A ...
Company to pursue Phase 3 development strategy designed to deliver best-in-class efficacy with a high-dose quarterly regimen ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する